QualityStocks would like to highlight Power of the Dream Ventures, Inc. (OTCBB: PWRV). The company acquires or works with Hungarian companies with technology patents, such as Genetic Immunity, a wholly owned subsidiary of Power of the Dream Ventures. Genetic Immunity is a US/Hungarian clinical-stage biotechnology company focusing on the discovery, development and commercialization of a new class of immunotherapeutic biologics for the treatment of chronic viral infections, cancer, and allergy.
In the company’s news yesterday,
Genetic Immunity, a wholly owned subsidiary of Power of the Dream Ventures, announced the peer-reviewed publication, “Nanomedicine applications Towards the Cure of HIV,” covering the company’s nanotechnology and detailing its potential for the cure of HIV.
To provide background of the technology the company explains: the scientists of Genetic Immunity described their research for the cure of HIV in an article in the May 1999 issue of the New England Journal of Medicine. The article features “the Berlin patient,” the first patient whose immune system was boosted to control HIV after he elected to stop his daily drug treatment (http://www.nejm.org/doi/full/10.1056/NEJM199905273402114). It was observation of this scenario that the company says inspired development of DermaVir, a drug that boosts the immune system to specifically recognize and kill HIV infected cells. Fast-forward to-date, and DermaVir is the most advanced nanomedicine developed for the cure of HIV, says Genetic Immunity.
“We have about 30 potent HIV drugs suppressing viral load, but we do not have any to eliminate the infected cells from the reservoirs. To cure HIV we need new drugs to activate these infected cells and to kill them. In our manuscript we described the new drugs that are needed and the strategy that will result in the cure of HIV. One of these new essential drugs for HIV eradication is DermaVir, our lead HIV-specific immunotherapeutic product,” Genetic Immunity CEO Dr. Julianna Lisziewicz stated in the press release.
Dr. Lisziewicz explains that in contrast to daily oral drugs for the treatment of HIV, DermaVir is administered only a few times a year with four patches. In the company’s clinical trials, DermaVir was shown safe as a placebo and effective in inducing long-lasting HIV-specific T cell production.
“Our GIEU006 phase II trial demonstrated significant killing of HIV-infected cells, producing 70 percent viral load reduction compared to a placebo. Our results suggest that DermaVir provides the immunologic drug component toward the eradication of HIV,” Dr. Lisziewicz concluded.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
